Therefore, this study aimed to assess the effects of the anti-diabetes drug Exendin-4 (Exe-4), a GLP-1 receptor agonist (25), on the response of human endometrial cancer cells to chemotherapy after prolonged exposure to HG. Here, GLP1R is linked to endometrial cancer.